
    
      Population: Patients with advanced progressive 131I-refractory DTC or MTC will be enrolled to
      this study. Forty-five patients responding to TKI therapy (defined as 50% drop in tumor
      marker level within the first two months of treatment) will be randomized to receive TKI
      therapy either through adaptive (intermittent) or conventional (continuous) regimen.
    
  